Shopping Cart

Your shopping cart is currently empty

Delcasertib

Name: Delcasertib
Brand: TargetMol
SKU: T11740
Price: 213 USD
Availability: InStock
Rating: 5 (10 reviews)

🥰Excellent

Catalog No. T11740Cas No. 949100-39-4

Alias KAI-9803, BMS-875944

Delcasertib (KAI-9803) is a potent and selective inhibitor of δ-protein kinase C (δPKC).

Delcasertib

🥰Excellent

Purity: 99.96%

Catalog No. T11740Alias KAI-9803, BMS-875944Cas No. 949100-39-4

Delcasertib (KAI-9803) is a potent and selective inhibitor of δ-protein kinase C (δPKC).

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$213	In Stock	In Stock
5 mg	$538	In Stock	In Stock
10 mg	$778	In Stock	In Stock
25 mg	$1,180	In Stock	In Stock
50 mg	$1,620	In Stock	In Stock
100 mg	$2,180	-	In Stock
1 mL x 10 mM (in DMSO)	$1,780	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.96%

Resource Download

COA LCMS

Product Introduction

Bioactivity

Description	Delcasertib (KAI-9803) is a potent and selective inhibitor of δ-protein kinase C (δPKC).
In vitro	Delcasertib is composed of a selective δ-protein kinase C (δPKC) inhibitor peptide derived from the δV1-1 portion of δPKC (termed 'cargo peptide”), conjugated reversibly to the cell-penetrating peptide 11-amino acid, arginine-rich sequence of the HIV type 1 transactivator protein (TAT47–57; termed 'carrier peptide”) via a disulfide bond.
In vivo	KAI-9803 ameliorates pathological conditions in acute myocardial infarction and reduce pain via specific modulation of membrane-translocation of PKC delta or epsilon. Delcasertib has an acceptable safety and tolerability profile when delivered via intracoronary injection during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.Delcasertib administration at the end of ischemia has been found to reduce cardiac damage caused by ischemia-reperfusion in a rat model of acute myocardial infarction. 14C-KAI-9803 is rapidly delivered to many tissues, including the heart (1.21 μg eq/g tissue), while being quickly cleared from the systemic circulation. The distribution of Delcasertib to tissues such as the liver, kidney, and heart is facilitated by the reversible conjugation to TAT47–57.
Synonyms	KAI-9803, BMS-875944

Chemical Properties

Molecular Weight	2880.28
Formula	C₁₂₀H₁₉₉N₄₅O₃₄S₂
Cas No.	949100-39-4
Smiles	[C@H](CC1=CC=C(O)C=C1)(C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@@H](CC(C)C)C(O)=O)=O)CO)=O)=O)CC(C)C)=O)CCC(O)=O)=O)NC([C@@H](NC([C@@H](NC([C@H](CC2=CC=CC=C2)NC([C@@H](NC([C@H](CSSC[C@@H](C(N[C@@H](CC3=CC=C(O)C=C3)C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCNC(=N)N)C(O)=O)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CCC(N)=O)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CCCCN)=O)CCCCN)=O)CCCNC(=N)N)=O)=O)=O)N)N)=O)CO)=O)=O)CC(N)=O)=O)CO)=O
Relative Density.	1.54 g/cm3 (Predicted)
Sequence Short	Sequence 1:CYGRKKRRQRRR;Sequence 1':CSFNSYELGSL (Disulfide bridge:Cys1-Cys1’)

Storage & Solubility Information

Storage

keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 99 mg/mL (34.37 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (1.74 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	0.3472 mL	1.7359 mL	3.4719 mL	17.3594 mL
5 mM	0.0694 mL	0.3472 mL	0.6944 mL	3.4719 mL
10 mM	0.0347 mL	0.1736 mL	0.3472 mL	1.7359 mL
20 mM	0.0174 mL	0.0868 mL	0.1736 mL	0.8680 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:

For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments

A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent

DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH₂O. So your working solution concentration is 2 mg/mL。

Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO TargetMol | reagent

(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.

Preparation method for in vivo formula: Take 50 μL DMSO TargetMol | reagent

main solution, add 300 μLPEG300 TargetMol | reagent

mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH₂O TargetMol | reagent

mix well and clarify

For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.

All types of co-solvents required for the protocol, such asDMSO, PEG300/ PEG400, Tween 80, SBE-β-CD, corn oil are available for purchase on the TargetMol website with a simple click.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc